Orally Available Small Molecule Regulates TXNIP Expression and Glucagon Action for the Treatment of Diabetes

Authors:

Abstract
In the progression of diabetes, sustained glucagon secretion facilitates glucose production. Despite its significance, no treatments currently target this vital parameter. We employed the promoter sequence of thioredoxin-interacting protein (TXNIP) as a screening target, evaluated our in-house chemical library, and subsequently undertook high-throughput screening and optimization via various medicinal chemistry techniques. Our efforts led to the identification of SKL-1223, an orally administered, non-toxic small molecule capable of effectively regulating blood glucose levels in both streptozotocin-induced and obesity-induced (db/db) diabetic mice. Furthermore, our study elucidated the hypoglycemic effect of glucagon and its role in reducing hepatic glucose output. On a mechanistic level, SKL-1223 interacts with the E-box region of the TXNIP promoter, consequently suppressing TXNIP transcription and associated signaling pathways. Thus, our study introduces a novel compound, offering a fresh therapeutic avenue for diabetes beyond existing regimens.